# Core G: Biomarker Core

> **NIH NIH P30** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2021 · $733,533

## Abstract

ABSTRACT
In the past five years, the UCSF ADRC Biospecimens and Genetics sub-cores (as part of the Neuropathology
Core) have experienced tremendous success with collection, banking, genotyping and dissemination of human
biospecimens, contributing more samples to the National Cell Repository for Alzheimer’s Disease (NCRAD) than
any other ADRC. This new, proposed Biomarker Core will build on these strengths to support the UCSF ADRC’s
mission of improving the early and accurate diagnosis of neurodegenerative disease. By banking and sharing a
large, longitudinal collection of exquisitely well-characterized patient and control plasma, CSF, DNA and
fibroblasts, we will be positioned to support research projects locally, nationally and internationally. The Clinical
Core will refer ADRC subjects for fluid and cell collection which will be collaborative managed by the Biomarker
Core (for storage, analysis and sharing) and Data Management Core (for web-based query tools and safe and
compliant data storage and deposition.) Information will be shared with the Neuroimaging and Neuropathology
Cores to drive scientific insights into disease pathophysiology. This Core will continue to genotype all ADRC
participants for risk genes and alleles in collaboration with UCLA. We propose to add baseline characterization
of CSF to include total tau (T-tau), phospho-tau (P-tau) and Abeta 40 and 42. We will also expand the toolbox of
Biomarkers through investigation of novel fluid and genetic biomarkers and characterization of AD and ADRD
epithelial fibroblasts. In Aim 1 we collect, store, track, share and analyze human blood, plasma, CSF and dermal
fibroblasts. In Aim 2 we leverage existing projects to expand the toolbox of biomarkers for neurodegenerative
diseases. The goal of Aim 3 is to attract new scientists to and promote interest in biomarker-based clinical and
translational research through education and support of pilot projects. These contributions are significant
because they will both build the foundation and push the leading edge of productive and sustainable biomarker
development in Alzheimer’s Disease and related disorders. Together, this repository will help investigators begin
to unravel the heterogeneity of these disease with the ultimate goal of improving therapies.

## Key facts

- **NIH application ID:** 10131101
- **Project number:** 5P30AG062422-03
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** Aimee Kao
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $733,533
- **Award type:** 5
- **Project period:** 2019-05-01 → 2024-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10131101

## Citation

> US National Institutes of Health, RePORTER application 10131101, Core G: Biomarker Core (5P30AG062422-03). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10131101. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*